BP2301 / BrightPath Biotherap - LARVOL DELTA

Brightpath - Rebounds for the First Time in 9 Days Receives Notice of Allowance for Patent on "BP2301" [Google translation] (Yahoo Finance) - "BrightPath Bio Inc...has rebounded for the first time in nine days. On the 22nd, the company announced that it had received a notice of allowance from the Japan Patent Office for a patent application it had filed with Shinshu University and Kyoto Prefectural University of Medicine regarding 'BP2301,' which it is developing....The patent is said to be for a manufacturing method of CAR-T cells using artificially created antigen-presenting cells. There are no restrictions on antigens or types of T cells, making it a patent with a broad scope of rights. The patent has also been applied for in China, Europe, and the United States, and the review is proceeding smoothly."

Patent • Oncology • Solid Tumor

PiggyBac transposon-mediated HER2-CAR-T cells exert anti-tumor efficacy against cholangiocarcinoma (SITC 2023) - "The efficacy of BP2301 in treating CCA was evaluated using Sik01, a CCA patient-derived cell line with moderate HER2 expression that did not respond to Trastuzumab emtansine (T-DM1). Currently, a phase 1 clinical trial is ongoing to evaluate the safety and efficacy of BP2301 in HER2-expressing sarcoma and gynecologic malignancies. Our results about anti-tumor efficacy against CCA provide support for the future development of BP2301 as a potential treatment option for CCA patients with HER2 expression."

CAR T-Cell Therapy • Clinical • IO biomarker • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Sarcoma • Solid Tumor • CD8 • CD80 • HER-2